Last updated: November 12, 2024
Sponsor: Rutgers, The State University of New Jersey
Overall Status: Active - Recruiting
Phase
N/A
Condition
Obesity
Transplant Rejection
Diabetes Prevention
Treatment
Institutional standard intravenous immune globulin treatment
Clinical Study ID
NCT04818177
Pro20160000739
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
aged 18 to 75 years
currently treated with IVIG
Exclusion
Exclusion Criteria:
liver impairment (elevations in liver enzymes of greater than 3 times the upperlimit of normal)
reduced renal function (CrCl < 50 mL/min)
Patients with a pacemaker or an automatic implantable cardioverter-defibrillator
Study Design
Total Participants: 40
Treatment Group(s): 1
Primary Treatment: Institutional standard intravenous immune globulin treatment
Phase:
Study Start date:
April 02, 2021
Estimated Completion Date:
December 01, 2025
Study Description
Connect with a study center
Robert Wood Johnson University Hospital Somerset
Somerville, New Jersey 08876
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.